Physician profile
Peter Fumo
NPI 1366425092
$1,001.85
in general payments reported to CMS, 2019-2025
16 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $132 · 2022: $46.33 · 2023: $153 · 2024: $97.34 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $281.81 | 2019-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $123.03 | 2020-2025 | Farxiga |
| Calliditas Therapeutics US INC. | $121.32 | 2024-2025 | Tarpeyo |
| Bard Peripheral Vascular, INC. | $66.09 | 2020 | |
| Lilly USA, LLC | $54.89 | 2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $51.45 | 2023 | Lupkynis |
| Daiichi Sankyo INC. | $47.34 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.55 | 2022-2025 | |
| Travere Therapeutics, INC. | $44.47 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $43.16 | 2019 | |
| Veloxis Pharmaceuticals, INC. | $25.57 | 2019 | |
| Ardelyx, INC. | $25.57 | 2024 | Ibsrela |
| Opko Pharmaceuticals, LLC | $21.81 | 2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $19.73 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.85 | 2023 | Oxlumo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14.21 | 2023 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Fumo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.